For Research Use Only. Not for Human Consumption.
Recorded market$49.73Recorded exact-size market estimate: 49.73 USD for one 10 mg container (4.973300 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$49.00Member price$27.8743.9% lessMembers save $21.86 on this item vs. recorded market
Cyclic alpha-MSH analog for melanocortin research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$2.79/mg43.9% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:18 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Prism Labs Oct 10, 2026 UTC | One 10 mg container; 34.99 USD | $3.50/mg | powder; in_stock Primarytitle/mt2productURLidentifyMelanotanII;10mglyophilizedvial,1bottle,USDJSONLD34.99. Ageoverlaynotaccepted;15%couponexcluded. Fresh identity screenshot prism-mt210-identity-audit.png confirmsMelanotanII(MT-2)10MG. Price observation; no COA authentication is implied by inclusion. |
| Peptara Labs Oct 10, 2026 UTC | One 10 mg container; 140.00 USD | $14.00/mg | powder; in_stock Explicitone10mglyophilizedpowdervial140USD,complimentarybacteriostaticwaterincludedinorder;multi-vial/emaildiscountsexcluded. Price observation; no COA authentication is implied by inclusion. |
| Liberty Peptides Oct 10, 2026 UTC | One 10 mg container; 25.35 USD | $2.54/mg | powder; in_stock Explicitunitquantity1vial10mglyophilizedpowder;25.35USDpublicsale(list39). Labeled10mg,COAmeasured8.83mg notednominalnotquantityscaling. Price observation; no COA authentication is implied by inclusion. |
| Melanotan2USA Oct 11, 2026 UTC | One 10 mg container; 39.00 USD | $3.90/mg | powder; Addtocartavailable Current39USDpublicsale40list;explicitsinglevialwhitepowder. Price observation; no COA authentication is implied by inclusion. |
| Arctic Lab Supply Oct 11, 2026 UTC | One 10 mg container; 37.99 USD | $3.80/mg | lyophilized powder; publicly_listed Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 11, 2026 UTC | One 10 mg container; 35.00 USD | $3.50/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| USA Peptide Science Oct 11, 2026 UTC | One 10 mg container; 70.00 USD | $7.00/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Orion Peptides Oct 11, 2026 UTC | One 10 mg container; 45.00 USD | $4.50/mg | lyophilized powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Cell Peptides Oct 11, 2026 UTC | One 10 mg container; 39.00 USD | $3.90/mg | lyophilized powder; listed_for_sale Exact10mg product; own Melanotan shipped dry/reconstitution paragraph, quantity1/vial photo/3+vials discounts confirmindividualvial. Public39USD selected visiblecurrencytabUSD (screenshot); other currenciesunselected. No stable entrygate. Bulkdiscountsignored. Price observation; no COA authentication is implied by inclusion. |
| ZPHC Store Oct 11, 2026 UTC | One 10 mg container; 31.00 USD | $3.10/mg | lyophilized powder; listed_for_sale Explicit10mg(1lyophilizedvial), ownFormpowder, package includesoneactivevial plusancillaryBACwater. Fullpackageprice31retainednosubtraction. FooterpricesexplicitUSDallregions. Noentrygate; onlynonblockingcookiebanner. NominalmanufacturerZPHC, not assumed clinicallyequivalent. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Melanotan 2 – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/melanotan-2-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/melanotan-2-10-mg/
A cyclic alpha-MSH analog with broad melanocortin-receptor activity, used in pigmentation and central-signaling research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Melanotan II is a cyclic melanocortin-receptor agonist investigated for pigmentation and other effects. A very small human pilot does not establish a safe cosmetic tanning treatment.
The original study identifies a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It is different from afamelanotide and bremelanotide.
A shared melanocortin target does not make approved products containing related molecules interchangeable with Melanotan II.
The directly reviewed human evidence consists of an early phase-I pilot with three volunteers and a later adverse-event case report. This combination provides a preliminary signal of biological activity and reasons for caution, not a reliable benefit-risk estimate for broad use.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Single-blind pilot phase-I study in three male volunteers Reading scope: PubMed bibliographic record and abstract |
The study observed pigmentation changes in two participants, alongside nausea, fatigue or somnolence and spontaneous erections. | The sample was extremely small and the exposure brief; it could not characterize uncommon harms or long-term effects. |
| Melanotan II: a possible cause of renal infarction: review of the literature and case report.
Clinical case report with a literature discussion Reading scope: PubMed bibliographic record and abstract |
The report describes renal infarction considered possibly related to Melanotan II exposure. | A case report cannot establish causation or incidence, and should not be presented as a controlled risk estimate. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Pigmentation is a measurable effect, but it is not evidence of protection from ultraviolet injury or a favorable long-term cosmetic safety profile.
The tiny pilot and later safety signal answer different questions. Neither should be omitted: a possible benefit signal is not a safety guarantee, and a case association is not proof that every exposure causes the event.
The early trial documented unwanted effects even during short observation. The renal case adds a serious reported concern while leaving causality uncertain.
The material and exposure in an online product may differ from the characterized research preparation, adding another uncertainty to any comparison.
The escalation in the three-person phase-I experiment was an exploratory research procedure, not a validated cosmetic regimen. This profile deliberately does not translate it into personal-use instructions.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Resolve whether the material is Melanotan II, afamelanotide or bremelanotide. Require an identity method able to support the specific cyclic peptide claimed, rather than a generic melanotan name.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. Those names refer to different molecules and specific prescription formulations. Their evidence cannot be transferred simply because all involve melanocortin signaling.
No. The pilot measured pigmentation, not prevention of skin cancer or a validated substitute for sun protection.
No. It is an individual clinical observation. It is important for safety review but cannot quantify how commonly such an event occurs.
This companion to the Melanotan II research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
The escalation in the three-person phase-I experiment was an exploratory research procedure, not a validated cosmetic regimen. This profile deliberately does not translate it into personal-use instructions.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.